Skip to main content
. 2024 Aug 18;17(8):1469–1476. doi: 10.18240/ijo.2024.08.12

Table 1. Basic information and treatment of patients.

No. Age/sex/eye Systemic medical history IOP (mm Hg) Initial BCVA Final BCVA Stage Retinal condition
CMT Laser treatment Anti-VEGF
Clock bits The lesion involved in the macula Hemorrhage Hyper-reflective scar ERM
1 24/M/OD Hypertension 17.9 5 5 2A 2 N N N P 636 P P
2 72/F/OS Hypertension 13.5 5 5 3A 10 N P N P 392 P P
3 58/F/OD Hypertension 15.5 4 4.2 2B 6 P N P P 782 P P
4 64/M/OS Hypertension 17 4.2 4.8 2A 9 N P N P 513 P P
5 56/M/OD Hypertension 14.2 4.2 5 2B 7 N N N N 291 P P
6 70/M/OS Hypertension 20.6 2 4 2B 12 P N P P 964 P P
7 60/F/OS Hypertension 14 2 2 2B 12 P P N N 129 P N
8 66/F/OS Hypertension 16 5 5 2A 7 N N N N 185 P P
9 48/M/OD None 17.8 5 5 2B 12 P P N N 385 P N
10 48/M/OS Hypertension 15.3 2 2 2B 12 P P P P 761 P N
11 66/M/OS Hypertension 17.2 4 4 2B 6 P N N N 482 P P
12 41/M/OD None 19 4.6 4.8 2B 12 P N N N 353 N P
13 59/M/OD Hypertension 14.5 4.8 4.3 2B 2 P N P P 434 N N
14 63/M/OS Hypertension 20 4.8 4.6 2B 1 P N P P 484 N P
15 65/F/OD Hypertension 16.2 4 4 2B 2 P N P N 304 P P

OD: Right eye; OS: Left eye; N: Negative; P: Positive; CMT: Central macular thickness; IOP: Intraocular pressure; VEGF: Vascular endothelial growth factor; BCVA: Best corrected visual acuity; ERM: Epiretinal membrane.